B
BRIDGEBIO PHARMA INC
NASDAQ: BBIO (BridgeBio Pharma, Inc.)
最近更新时间: 11小时之前65.04
-1.46 (-2.20%)
市场趋势
| 短期 | 中期 | ||
| 行业 | Biotechnology (US) | 混合的 | 看涨 |
| Biotechnology (全球的) | 混合的 | 看涨 | |
| 股票 | BridgeBio Pharma, Inc. | 混合的 | 看涨 |
AIStockmoo 评分
2.2
| 分析师共识 | NA |
| 内部交易活动 | NA |
| 价格波动 | 2.0 |
| 技术平均移动指标 | 5.0 |
| 技术振荡指标 | -0.5 |
| 平均 | 2.21 |
|
BridgeBio Pharma is a biotechnology company focused on discovering, developing, testing, and delivering transformative treatments for patients with genetic diseases. The company has four programs in its late-stage pipeline focusing on Mendelian disorders, oncology, and gene therapy. One of its key programs, Attruby (acoramidis) , is an orally administered small molecule designed to stabilize tetrameric transthyretin for the treatment of transthyretin amyloid cardiomyopathy. |
|
| 部门 | Healthcare |
| 行业 | Biotechnology |
| 投资方式 | Small Growth |
| 内部持股比例 | 4.97% |
| 机构持股比例 | 98.14% |
所有权
| 姓名 | 日期 | 持有股份 |
|---|---|---|
| Kohlberg Kravis Roberts & Co. L.P. | 30 Jun 2026 | 13,260,971 |
| Viking Global Investors Lp | 30 Jun 2026 | 9,949,219 |
| Aisling Capital Management Lp | 30 Jun 2026 | 4,589,611 |
该时间范围内无数据。
支撑、阻力和趋势线水平是由人工智能（AI）模型生成的，请谨慎解读。
投资组合